Y Intercept Hong Kong Ltd Raises Stock Holdings in NeoGenomics, Inc. $NEO

Y Intercept Hong Kong Ltd raised its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 67.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 139,809 shares of the medical research company’s stock after purchasing an additional 56,284 shares during the period. Y Intercept Hong Kong Ltd owned 0.11% of NeoGenomics worth $1,037,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. First Horizon Corp raised its stake in shares of NeoGenomics by 52.6% during the 4th quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock worth $30,000 after acquiring an additional 865 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of NeoGenomics by 110.2% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,968 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 1,556 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of NeoGenomics during the 4th quarter valued at $39,000. Smartleaf Asset Management LLC boosted its position in shares of NeoGenomics by 77.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 3,466 shares of the medical research company’s stock worth $42,000 after purchasing an additional 1,515 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in NeoGenomics by 68.2% during the 4th quarter. GAMMA Investing LLC now owns 3,602 shares of the medical research company’s stock worth $42,000 after buying an additional 1,460 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

NEO has been the topic of a number of research analyst reports. Benchmark upgraded NeoGenomics from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Wednesday, April 29th. Weiss Ratings cut shares of NeoGenomics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 29th. William Blair reissued a “market perform” rating on shares of NeoGenomics in a research report on Monday, March 16th. Leerink Partners upgraded NeoGenomics from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $12.00 to $25.00 in a research note on Wednesday, April 29th. Finally, TD Cowen increased their price objective on NeoGenomics from $13.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Six investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $13.86.

Insider Transactions at NeoGenomics

In other NeoGenomics news, Director Lynn A. Tetrault sold 5,307 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $11.29, for a total value of $59,916.03. Following the sale, the director owned 91,422 shares in the company, valued at approximately $1,032,154.38. This represents a 5.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.10% of the company’s stock.

NeoGenomics Stock Performance

NASDAQ NEO traded down $0.62 on Friday, reaching $14.11. 1,377,877 shares of the company’s stock traded hands, compared to its average volume of 3,692,974. NeoGenomics, Inc. has a fifty-two week low of $4.72 and a fifty-two week high of $15.57. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.06 and a current ratio of 4.42. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of -18.32 and a beta of 1.74. The stock has a 50 day moving average price of $11.08 and a 200-day moving average price of $10.50.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, April 28th. The medical research company reported $0.01 earnings per share for the quarter, hitting the consensus estimate of $0.01. The company had revenue of $186.67 million for the quarter, compared to the consensus estimate of $184.54 million. NeoGenomics had a negative return on equity of 2.80% and a negative net margin of 13.30%.NeoGenomics’s quarterly revenue was up 11.3% compared to the same quarter last year. Equities research analysts predict that NeoGenomics, Inc. will post -0.15 EPS for the current fiscal year.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.